A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial

20246 citationsJournal Articlehybrid Open Access

Authors

Joshua J. Solomon · National Jewish Health

Robert W. Hallowell · Massachusetts General Hospital

Cecilia Ganslandt · Vicore Pharma (Sweden)

Jessica Shull · Vicore Pharma (Sweden)

Thomas Bengtsson · Vicore Pharma (Sweden)

Jakob Ganslandt · Vicore Pharma (Sweden)

Maureen R. Horton

Abstract

Treatment with Almee was well-tolerated and showed clinically meaningful improvement in pulmonary fibrosis-related anxiety. Almee shows promise as a personalized intervention for management of the psychological burden related to living with pulmonary fibrosis.

Topics & Keywords

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Respiratory and Cough-Related Research Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Respirology

Volume 30, Issue 3, pp. 253-261

DOI: 10.1111/resp.14859

Field-Weighted Citation Impact: 2.48